Lithium: clinical trials recruiting now
5
Recruiting trials
10
Conditions studied
18
US states with sites
24
Countries
FDA drug label
- FDA-approved
- Yes. Lithium appears in the FDA drug-label database. Marketed as Lithium.
- Boxed warning
- The FDA label for Lithium carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 ) ] Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 ) ] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) Maintenance treatment in patients 7 years and older ( 1 )
Phase breakdown
Phase 3 3
Phase 4 1
Not applicable 1
Conditions being studied
Recruiting trials involving Lithium
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
- Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Common questions
Is Lithium FDA-approved?
Yes, marketed as Lithium. Its FDA label carries a boxed warning.
How many recruiting trials involve Lithium?
5 recruiting trials across 10 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.